Lhrh Like Patents (Class 514/800)
  • Patent number: 9987270
    Abstract: The invention provides therapeutic methods and kits for treating a glioma using a particular dosing regimen of the organonitro compound ABDNAZ, radiation therapy, and one of temozolomide, irinotecan, or bevacizumab.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: June 5, 2018
    Assignee: EPICENTRIX, INC.
    Inventors: Bryan T. Oronsky, Jan Scicinski
  • Patent number: 7718599
    Abstract: The invention relates to pharmaceutical compositions suitable for parenteral administration comprising, peptides in the form of acetate, gluconate, glucuronate, lactate, citrate, ascorbate, benzoate or phosphate salts in dissolved or dispersed form and at least one of the acids for forming the salts in free acid form.
    Type: Grant
    Filed: May 18, 2001
    Date of Patent: May 18, 2010
    Assignee: AEterna Zentaris GmbH
    Inventors: Horst Bauer, Michael Damm, Werner Sarlikiotis
  • Patent number: 7696149
    Abstract: A method for preventing aggregation of an LHRH antagonist in a pharmaceutical composition. The method comprises combining the LHRH antagonist in the form of an acetate, gluconate, glucuronate, lactate, citrate, ascorbate, benzoate or phosphate salt and at least one of the acids for forming the salts in free acid form.
    Type: Grant
    Filed: January 4, 2005
    Date of Patent: April 13, 2010
    Assignee: AEterna Zentaris GmbH
    Inventors: Horst Bauer, Michael Damm, Werner Sarlikiotis
  • Patent number: 7605121
    Abstract: A novel lyophilizate and method of preparation as well as the use of the lyophilizate to treat female infertility and for gonad protection. Cetrorelix is dissolved in acetic acid 30% v/v, the solution is transferred to water and freeze dried.
    Type: Grant
    Filed: January 24, 2005
    Date of Patent: October 20, 2009
    Assignee: AEterna Zentaris GmbH
    Inventors: Jürgen Engel, Burkhard Wichert, Dieter Sauerbier, Gudrun Sauerbier, legal representative, Thomas Reissmann
  • Patent number: 7342048
    Abstract: A bioabsorbable release-sustaining pharmaceutical formulation using a biodegradable release-sustaining base material which can prevent an effective component drug from being released too rapidly just after administration of the formulation and then allow continued release of the drug for at least one month at a defined rate, is provided. For the biodegradable release-sustaining base material, a lactic acid-glycolic acid copolymer (PLGA) with an adjusted distribution in molecular weight is used.
    Type: Grant
    Filed: April 25, 2006
    Date of Patent: March 11, 2008
    Assignee: Nipro Corporation
    Inventors: Tatsuaki Miyaji, Makoto Sato, Tamaki Murayama, Yohei Hoashi, Hisae Saito, Takao Okada, Yukari Imamura, Yoshimichi Fujiyama
  • Patent number: 7288517
    Abstract: The present invention relates to the treatment of dementia and neurodegenerative diseases like Alzheimer's disease with intermediate doses of LHRH antagonists which do not cause a castration. A preferred LHRH antagonist is cetrorelix.
    Type: Grant
    Filed: April 27, 2002
    Date of Patent: October 30, 2007
    Assignee: AEterna Zentaris GmbH
    Inventors: Jürgen Engel, Rainer Voegeli
  • Patent number: 6867181
    Abstract: A method of spherifying a sustained release ionic conjugate which contains a free carboxyl group-containing polymer and a free amino group-containing drug which are ionically bonded to each other.
    Type: Grant
    Filed: January 26, 2000
    Date of Patent: March 15, 2005
    Assignees: Societe de Conseils de Recherches et d'Applications Scientifiques, S.A.S., Poly-Med, Incorporated
    Inventors: Shalaby Wahba Shalaby, Steven A. Jackson, Jacques-Pierre Moreau
  • Patent number: 6867191
    Abstract: A lyophilizate, method of preparation, and use of the lyophilizate for gonad protection is described. The lyophilizate comprises cetrorelix dissolved in 30% (v/v) acetic acid, transferred to water, and freeze-dried.
    Type: Grant
    Filed: May 24, 2002
    Date of Patent: March 15, 2005
    Assignee: Zentaris GmbH
    Inventors: Jürgen Engel, Burkhard Wichert, Dieter Sauerbier, Thomas Reissmann
  • Patent number: 6863891
    Abstract: A novel lyophilizate and method of preparation as well as the use of the lyophilizate to treat female infertility and for gonad protection. Cetrorelix is dissolved in acetic acid 30% v/v, the solution is transferred to water and freeze dried.
    Type: Grant
    Filed: January 9, 2002
    Date of Patent: March 8, 2005
    Assignee: Zentaris AG
    Inventors: Jürgen Engel, Burkhard Wichert, Dieter Sauerbier, Thomas Reissmann
  • Patent number: 6703367
    Abstract: Methods to inhibit hot flashes or gynaecomastia in a subject are provided. In the methods of the invention, an LHRH antagonist is administered to a subject in need of treatment for hot flashes or gynaecomastia such that hot flashes or gynaecomastia are inhibited in the subject. In a particularly preferred embodiment, the invention provides a method for inhibiting menopause-related hot flashes in which an LHRH antagonist is administered to a subject in need of treatment for menopause-related hot flashes such that the hot flashes are inhibited in the subject.
    Type: Grant
    Filed: February 16, 2001
    Date of Patent: March 9, 2004
    Assignee: Praecis Pharmaceuticals Inc.
    Inventor: Marc B. Garnick
  • Patent number: 6699833
    Abstract: Sustained delivery formulations comprising a water-insoluble complex of a peptide and a carrier macromolecule are disclosed. The formulations of the invention allow for loading of high concentrations of peptide in a small volume and for delivery of a pharmaceutically active peptide for prolonged periods, e.g., one month, after administration of the complex. The complexes of the invention can be milled or crushed to a fine powder. In powdered form, the complexes form stable aqueous suspensions and dispersions, suitable for injection. In a preferred embodiment, the peptide of the complex is an LHRH analogue, preferably an LHRH antagonist, and the carrier macromolecule is an anionic polymer, preferably carboxymethylcellulose. Methods of making the complexes of the invention, and methods of using LHRH-analogue-containing complexes to treat conditions treatable with an LHRH analogue, are also disclosed.
    Type: Grant
    Filed: July 8, 1999
    Date of Patent: March 2, 2004
    Assignee: Praecis Pharmaceuticals, Inc.
    Inventors: Malcolm L. Gefter, Nicholas Barker, Gary Musso, Christopher J. Molineaux
  • Patent number: 6593096
    Abstract: An agent for cancer immunotherapy with independent use, containing bacterial components as an active ingredient, which induces cancer patients to exhibit immune responsiveness, as indicated by the increase of interferon-&ggr; and CD28 markers in peripheral blood, when administered to an immuno-competent patient intracutaneously.
    Type: Grant
    Filed: December 20, 1999
    Date of Patent: July 15, 2003
    Inventors: Akira Hayashi, Ichiro Azuma, Kumao Toyoshima
  • Patent number: 6423334
    Abstract: A composition for enteral administration having a non-ionic vegetable oil GIT absorption enhancer capable of increasing the enteral absorbability of drugs, especially oral absorbability of hydrophilic and macromolecular drugs. The non-ionic vegetable oil GIT absorption enhancer, particularly Babassu oil or a derivative thereof, is capable of enhancing the uptake of a drug from the gastrointestinal tract so as to allow therapeutically effective amounts of the drug to be transported across the GIT of an animal such as a human without significant toxic side effects.
    Type: Grant
    Filed: September 30, 1998
    Date of Patent: July 23, 2002
    Assignee: Elan Corporation, plc
    Inventors: David J. Brayden, Jacqueline M. Dee
  • Patent number: 6384017
    Abstract: Methods for treating prostate cancer are disclosed. The methods of the invention generally feature administration to a subject of an LHRH-R antagonist, in combination with a second therapy. In one embodiment, this second therapy is performance of a procedure that removes or destroys prostatic tumor tissue, such as a radical prostatectomy, cryosurgery or X-ray therapy (external or interstitial). In another embodiment, the second therapy is treatment with an LHRH-R agonist, either simultaneous with or subsequent to LHRH-R antagonist therapy. The methods of the invention can further involve administering an antiandrogen and/or an inhibitor of sex steroid biosynthesis to the subject in combination with the LHRH-R antagonist.
    Type: Grant
    Filed: October 26, 2000
    Date of Patent: May 7, 2002
    Assignee: Praecis Pharmaceuticals, Inc.
    Inventors: Marc B. Garnick, Christopher J. Molineaux, Malcolm L. Gefter
  • Patent number: 6303123
    Abstract: Immunogenic compositions capable of generating an immune response in mammals against GnRH are disclosed. The immunogenic compositions are effective in methods of treating gonadotropin and gonadal steroid hormone dependent diseases and immunological contraception of mammals.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 16, 2001
    Assignee: Aphton Corporation
    Inventors: Stephen Grimes, Robert Scibienski
  • Patent number: 6265393
    Abstract: Methods and articles of manufacture are provided for the long-term prevention of clinical symptoms and signs produced by endometriosis. Such methods and articles of manufacture involve the continuous coadministration of low doses of an estrogen agent and a progestin agent to maintain an induced state of oligomenorrhea or amenorrhea in an afflicted woman.
    Type: Grant
    Filed: August 7, 1998
    Date of Patent: July 24, 2001
    Inventor: William LeRoy Heinrichs
  • Patent number: 6221958
    Abstract: Disclosed is a sustained release pharmaceutical composition. The composition includes a polyester containing a free COOH group ionically conjugated with a bioactive polypeptide comprising at least one effective ionogenic amine, wherein at least 50% by weight of the polypeptide present in the composition is ionically conjugated to the polyester.
    Type: Grant
    Filed: January 26, 1999
    Date of Patent: April 24, 2001
    Assignees: Societe de Conseils de Recherches et d'Applications Scientifiques, SAS, Poly-Med Incorporated
    Inventors: Shalaby Wahba Shalaby, Steven A. Jackson, Jacques-Pierre Moreau
  • Patent number: 6214969
    Abstract: The present invention deals with LHRH analogs which contain cytotoxic moieties, have influence on the release of gonadotropins from the pituitary in mammals (possess high agonistic or antagonistic activity) and have antineoplastic effect.
    Type: Grant
    Filed: January 25, 1993
    Date of Patent: April 10, 2001
    Assignee: The Administrators of the Tulane Educational Fund
    Inventors: Tamas Janaky, Attila Juhasz, Sandor Bajusz, Andrew V. Schally
  • Patent number: 6214798
    Abstract: Peptides are provided which have improved duration of GnRH antagonistic properties. These antagonists may be used to regulate fertility and to treat steroid-dependent tumors and for other short-term and long-term treatment indications. These antagonists have a derivative of aminoPhe or its equivalent in the 5- or the 5- and 6-positions. This derivative is modified so as to contain a carbamoyl group or heterocycle, including a urea moiety, in its side chain. Decapeptides having the formula: Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph(L-hydroorotyl)-D-4Amf(Q2)-Leu-Lys(isopropyl)-Pro-Xaa10, wherein Q2 is Cbm or MeCbm and Xaa10 is D-Ala-ol or Ala-ol are particularly effective and continue to exhibit very substantial suppression of LH secretion at 96 hours following injection.
    Type: Grant
    Filed: January 3, 2000
    Date of Patent: April 10, 2001
    Assignee: Ferring BV
    Inventors: Graeme Semple, Guangcheng Jiang
  • Patent number: 6180608
    Abstract: Sustained delivery formulations comprising a water-insoluble complex of a peptidic compound (e.g., a peptide, polypeptide, protein, peptidomimetic or the like) and a carrier macromolecule are disclosed. The formulations of the invention allow for loading of high concentrations of peptidic compound in a small volume and for delivery of a pharmaceutically active peptidic compound for prolonged periods, e.g., one month, after administration of the complex. The complexes of the invention can be milled or crushed to a fine powder. In powdered form, the complexes form stable aqueous suspensions and dispersions, suitable for injection. In a preferred embodiment, the peptidic compound of the complex is an LHRH analogue, preferably an LHRH antagonist, and the carrier macromolecule is an anionic polymer, preferably carboxymethylcellulose. Methods of making the complexes of the invention, and methods of using LHRH-analogue-containing complexes to treat conditions treatable with an LHRH analogue, are also disclosed.
    Type: Grant
    Filed: December 11, 1997
    Date of Patent: January 30, 2001
    Assignee: Praecis Pharmaceuticals, Inc.
    Inventors: Malcolm L. Gefter, Nicholas Barker, Gary Musso, Christopher J. Molineaux
  • Patent number: 6153586
    Abstract: Methods for treating prostate cancer are disclosed. The methods of the invention generally feature administration to a subject of an LHRH-R antagonist, in combination with a second therapy. In one embodiment, this second therapy is performance of a procedure that removes or destroys prostatic tumor tissue, such as a radical prostatectomy, cryosurgery or X-ray therapy (external or interstitial). In another embodiment, the second therapy is treatment with an LHRH-R agonist, either simultaneous with or subsequent to LHRH-R antagonist therapy. The methods of the invention can further involve administering an antiandrogen and/or an inhibitor of sex steroid biosynthesis to the subject in combination with the LHRH-R antagonist.
    Type: Grant
    Filed: July 1, 1998
    Date of Patent: November 28, 2000
    Assignee: Praecis Pharmaceuticals, Inc.
    Inventors: Marc B. Garnick, Christopher J. Molineaux, Malcolm L. Gefter
  • Patent number: 6132720
    Abstract: Immunogenic compositions capable of generating an immune response in mammals against GnRH are disclosed. The immunogenic compositions are effective in methods of treating gonadotropin and gonadal steroid hormone dependent diseases and immunological contraception of mammals.
    Type: Grant
    Filed: November 17, 1997
    Date of Patent: October 17, 2000
    Assignee: Aphton Corp.
    Inventors: Stephen Grimes, Robert Scibienski
  • Patent number: 6106805
    Abstract: The invention relates to a diagnostic composition for improving the effectiveness of hysteroscopy, characterized in that it contains an LH-RH antagonist, in particular cetrorelix. The composition is envisaged for use prior to hysteroscopy and/or for preparation for surgery, specifically in a single dose of between 0.1 and 2 mg/kg.However, the composition can also be administered, for use prior to hysteroscopy and/or for preparation for surgery, in a multiple dose of between 0.01 and 0.5 mg/kg, preferably spread over 1-14 days. The composition is furthermore suitable for use in hysteroscopy in combination with the subsequent treatment of pathological conditions of the uterus such as myoma and endometrial hyperplasia.
    Type: Grant
    Filed: October 30, 1997
    Date of Patent: August 22, 2000
    Assignee: Asta Medica Aktiengesellschaft
    Inventors: Jurgen Engel, Klaus Diedrich, Ricardo Felberbaum
  • Patent number: 6034175
    Abstract: This invention relates to novel salts composed of a cation derived from a peptide containing at least one basic group and an anion derived from a carboxy-terminated polyester, processes for the manufacture of such salts, and the use of such salts in the manufacture of extended release pharmaceutical compositions. The salts of the invention possess a variety of properties which are useful in the formulation of extended release pharmaceutical compositions, whether the salts are in pure form or are in admixture with either an excess of the peptide in its free, unbound form or an excess of the free polyester.
    Type: Grant
    Filed: January 22, 1999
    Date of Patent: March 7, 2000
    Assignee: Zeneca Limited
    Inventor: Francis Gowland Hutchinson
  • Patent number: 5985834
    Abstract: Described are LHRH-antagonistic and bombesin-antagonistic nona- and decapeptides suitable for use in the preparation of a drug for the treatment of AIDS and ARC as well as for use in the preparation of an immunostimulation drug.
    Type: Grant
    Filed: December 18, 1995
    Date of Patent: November 16, 1999
    Assignee: ASTA Medica AG
    Inventors: Jurgen Engel, Bernhard Kutscher, Michael Bernd, Ulf Niemeyer
  • Patent number: 5968895
    Abstract: Sustained delivery formulations comprising a water-insoluble complex of a peptide and a carrier macromolecule are disclosed. The formulations of the invention allow for loading of high concentrations of peptide in a small volume and for delivery of a pharmaceutically active peptide for prolonged periods, e.g., one month, after administration of the complex. The complexes of the invention can be milled or crushed to a fine powder. In powdered form, the complexes form stable aqueous suspensions and dispersions, suitable for injection. In a preferred embodiment, the peptide of the complex is an LHRH analogue, preferably an LHRH antagonist, and the carrier macromolecule is an anionic polymer, preferably carboxymethylcellulose. Methods of making the complexes of the invention, and methods of using LHRH-analogue-containing complexes to treat conditions treatable with an LHRH analogue, are also disclosed.
    Type: Grant
    Filed: December 11, 1996
    Date of Patent: October 19, 1999
    Assignee: Praecis Pharmaceuticals, Inc.
    Inventors: Malcolm L. Gefter, Nicholas Barker, Gary Musso, Christopher J. Molineaux
  • Patent number: 5929028
    Abstract: The invention concerns a liquid gonadotropin-containing formulation characterised in that the formulation comprises a gonadotropin and stabilising amounts of a polycarboxylic acid or a salt thereof and of a thioether compound. The particular proteins (e.g. LH, TSH, FSH, or HCG) are in admixture with the particular stabilizers in an aqueous solution. The preparations contain a sufficient amount of the polycarboxylic acid or a salt thereof, preferably sodium citrate, and a sufficient amount of the thioether compound, preferably methionine, to stabilize the protein. The preparations preferably also include a nonreducing disaccharide like sucrose, and a non-ionic surfactant.
    Type: Grant
    Filed: April 14, 1998
    Date of Patent: July 27, 1999
    Assignee: Akzo Nobel, N.V.
    Inventors: Arnold Titus Philip Skrabanja, Petrus Johannes Maria van den Oetelaar
  • Patent number: 5925730
    Abstract: Peptides are provided which have improved duration of GnRH antagonistic properties. These antagonists may be used to regulate fertility and to treat steroid-dependent tumors and for other short-term and long-term treatment indications. These antagonists have a derivative of aminoPhe or its equivalent in the 5- and/or 6-positions. This derivative contains a carbamoyl group or a heterocycle including a urea in its side chain. Particularly effective decapeptides, which continue to exhibit very substantial suppression of LH secretion at 96 hours following injection, have the formulae: Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph(hydroorotyl)-D-4Aph(acetyl)-Leu-Lys(isopr opyl)-Pro-D-Ala-NH.sub.2, and Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph(hydroorotyl)-D-4Amf(Q.sub.2)-Leu-Lys(isop ropyl)-Pro-D-Ala-NH.sub.2, wherein Q.sub.2 is Cbm or MeCbm.
    Type: Grant
    Filed: April 11, 1997
    Date of Patent: July 20, 1999
    Assignee: Ferring BV
    Inventors: Graeme Semple, Guangcheng Jiang
  • Patent number: 5889110
    Abstract: This invention relates to novel salts composed of a cation derived from a peptide containing at least one basic group and an anion derived from a carboxy-terminated polyester, processes for the manufacture of such salts, and the use of such salts in the manufacture of extended release pharmaceutical compositions. The salts of the invention possess a variety of properties which are useful in the formulation of extended release pharmaceutical compositions, whether the salts are in pure form or are in admixture with either an excess of the peptide in its free, unbound form or an excess of the free polyester.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: March 30, 1999
    Assignee: Zeneca Limited
    Inventor: Francis Gowland Hutchinson
  • Patent number: 5877148
    Abstract: Methods useful for treating cancers are disclosed. The methods involve administering human chorionic gonadotropin (hCG) or human luteinizing hormone (hLH) to patients having cancers. Articles of manufacture that are useful for carrying out the described methods are also described. The claimed methods are effective against breast, prostate, ovary, and stomach carcinomas, as well as neuroblastomas, and Kaposi's sarcoma, among others.
    Type: Grant
    Filed: June 6, 1997
    Date of Patent: March 2, 1999
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Yanto Lunardi-Iskandar, Robert C. Gallo, Joseph L. Bryant
  • Patent number: 5863985
    Abstract: Disclosed is a sustained release pharmaceutical composition. The composition includes a polyester containing a free COOH group ionically conjugated with a bioactive polypeptide comprising at least one effective ionogenic amine, wherein at least 50% by weight of the polypeptide present in the composition is ionically conjugated to the polyester.
    Type: Grant
    Filed: June 2, 1997
    Date of Patent: January 26, 1999
    Assignee: Kinerton Limited
    Inventors: Shalaby W. Shalaby, Steven A. Jackson, Jacques-Pierre Moreau
  • Patent number: 5853740
    Abstract: The present invention provides a uniform dispersion in aqueous medium of droplets comprising: (a) a core comprising water, a non-toxic C.sub.2 -C.sub.5 alkanol, a water-soluble drug, and a surfactant, and (b) a coating surrounding the core comprising one or more pharmaceutically acceptable oils. The compositions of the present invention are particularly useful for the oral delivery of therapeutic agents because of their potential for taste masking, prolonged action, and protection of the drug against the external environment and enzyme entrapment.
    Type: Grant
    Filed: August 7, 1996
    Date of Patent: December 29, 1998
    Assignee: Abbott Laboratories
    Inventors: Mou-Ying Fu Lu, Akwete L. Adjei, Hillard W. Johnson
  • Patent number: 5824548
    Abstract: Invitro incubation of primate embryos in the presence of gonadotrophin releasor hormone (GnRH) results in enhanced chorionic gonadotrophin production associated with increased survival and attachment of the embryos. Treatment of invitro fertilized embryos with GnRH can be used to improve implantation. Agonists of GnRH reduce attachment competence of embryos and are thereby useful as post-fertilization contraceptives.
    Type: Grant
    Filed: May 29, 1996
    Date of Patent: October 20, 1998
    Assignee: Wisconsin Alumni Research Foundation
    Inventor: John P. Hearn
  • Patent number: 5783562
    Abstract: A method is provided for the design and synthesis of Leuteinizing Hormone Releasing Hormone (LHRH) antagonists having exact amino acid sequences and containing 5-100 amino acids. This method can be used to produce peptides useful in treating disorders of the reproductive endocrine system, including endometriosis, precocious puberty, prostate cancer and breast cancer. Additionally, peptides produced by this method can be used as contraceptives for either males or females. Peptides produced by this method can further be employed in the diagnosis and treatment of infertility.
    Type: Grant
    Filed: May 23, 1995
    Date of Patent: July 21, 1998
    Assignee: Asta Medica Aktiengesellschaft
    Inventor: Xiao Shaobo
  • Patent number: 5780435
    Abstract: Methods for treating prostate cancer are disclosed. The methods of the invention generally feature administration to a subject of an LHRH-R antagonist, in combination with a second therapy. In one embodiment, this second therapy is performance of a procedure that removes or destroys prostatic tumor tissue, such as a radical prostatectomy, cryosurgery or X-ray therapy (external or interstitial). In another embodiment, the second therapy is treatment with an LHRH-R agonist, either simultaneous with or subsequent to LHRH-R antagonist therapy. The methods of the invention can further involve administering an antiandrogen and/or an inhibitor of sex steroid biosynthesis to the subject in combination with the LHRH-R antagonist.
    Type: Grant
    Filed: December 15, 1995
    Date of Patent: July 14, 1998
    Assignee: Praecis Pharmaceuticals Incorporated
    Inventors: Marc B. Garnick, Christopher J. Molineaux, Malcolm L. Gefter
  • Patent number: 5767082
    Abstract: Synthetic nona- and decapeptide LHRH antagonist analogs are disclosed, having a sterically hindered guanidino-substituted arginyl or homoarginyl residue at position 8, with no arginyl substituent at position 6.
    Type: Grant
    Filed: June 2, 1993
    Date of Patent: June 16, 1998
    Assignee: Syntex (U.S.A.) Inc.
    Inventors: John J. Nestor, Jr., Brian H. Vickery
  • Patent number: 5744450
    Abstract: Peptides which include unnatural amino acids and which either promote or inhibit the secretion of gonadotropins by the pituitary gland and inhibit the release of steroids by the gonads. Administration of an effective amount of such peptides that are GnRH antagonists prevents ovulation of female mammalian eggs and/or the release of steroids by the gonads and may be used to treat steroid-dependent tumors. The agonists can be used for control of reproduction processes, to treat precocious puberty, endometriosis, and the like. The peptides are analogs of the decapeptide GnRH wherein there is at least one residue of an unnatural amino acid in the 3-, 5-, 6- and/or 8-positions.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: April 28, 1998
    Assignee: The Salk Institute for Biological Studies
    Inventors: Carl A. Hoeger, Jean E. F. Rivier, Paula Guess Theobald, John S. Porter, Catherine L. Rivier, Wylie Walker Vale, Jr.
  • Patent number: 5712251
    Abstract: A method of treating prostate cancer in warm-blooded animals comprising administering to warm-blooded animals an effective amount of a peptide of Formula I and an anti-androgen.
    Type: Grant
    Filed: May 18, 1995
    Date of Patent: January 27, 1998
    Assignee: Roussel Uclaf
    Inventors: Fernand Labrie, Jean-Pierre Raynaud
  • Patent number: 5691314
    Abstract: A growth such as a tumor, hypertrophied tissue or cyst is biopsied or more completely excised subsequent to the administration of an effective amount of a gonadotropin releasing hormone analog or other inhibitor of ovarian steroid production or action.
    Type: Grant
    Filed: March 18, 1996
    Date of Patent: November 25, 1997
    Assignee: The Medical College of Hampton Roads
    Inventor: Gary D. Hodgen
  • Patent number: 5688506
    Abstract: Immunogenic compositions capable of generating an immune response in mammals against GnRH are disclosed. The immunogenic compositions are effective in methods of treating gonadotropin and gonadal steroid hormone dependent diseases and immunological contraception of mammals.
    Type: Grant
    Filed: January 27, 1994
    Date of Patent: November 18, 1997
    Assignee: Aphton Corp.
    Inventors: Stephen Grimes, Robert Scibienski
  • Patent number: 5677275
    Abstract: Methods useful for treating cancers are disclosed. The methods involve administering human chorionic gonadotropin (hCG) or human luteinizing hormone (hLH) to patients having cancers. Articles of manufacture that are useful for carrying out the described methods are also described. The claimed methods are effective against breast, prostate, ovary, and stomach carcinomas, as well as neuroblastomas, and Kaposi's sarcoma, among others.
    Type: Grant
    Filed: August 5, 1994
    Date of Patent: October 14, 1997
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Yanto Lunardi-Iskandar, Robert C. Gallo, Joseph L. Bryant
  • Patent number: 5672659
    Abstract: A composition including a polyester containing one or more free COOH groups ionically conjugated with a bioactive polypeptide comprising at least one effective ionogenic amine, wherein the polyester contains a member selected from the group of L-lactic acid, D-lactic acid, DL-lactic acid, .epsilon.-caprolactone, p-dioxanone, .epsilon.-caprolic acid, alkylene oxalate, cycloalkylene oxalate, alkylene succinate, .beta.-hydroxybutyrate, substituted or unsubstituted trimethylene carbonate, 1,5-dioxopan-2-one, 1,4-dioxepan-2-one, glycolide, glycolic acid, L-lactide, D-lactide, DL-lactide, meso-lactide, and any optically active isomers, racemates or copolymers thereof, and at least 50%, by weight, of the polypeptide present in the composition is ionically conjugated to said polyester.
    Type: Grant
    Filed: June 29, 1995
    Date of Patent: September 30, 1997
    Assignee: Kinerton Limited
    Inventors: Shalaby W. Shalaby, Steven A. Jackson, Jacques-Pierre Moreau
  • Patent number: 5663145
    Abstract: For application during the treatment of benign and malign tumour diseases, the product according to the invention containing the initial dose of Cetrorelix acetate and one or more maintenance doses of Cetrorelix acetate, Cetrorelix embonate or a slow-release form of Cetrorelix, is used as a combination preparation for treatment to be administered at specific time intervals.
    Type: Grant
    Filed: December 8, 1994
    Date of Patent: September 2, 1997
    Assignee: ASTA Medica Aktiengesellschaft
    Inventors: Jurgen Engel, Peter Hilgard, Thomas Reissmann
  • Patent number: 5643877
    Abstract: Novel peptide hormones which influence the release of gonadotropins by the pituitary gland in fish are disclosed. Methods in which such peptides may be administered to fish to control their reproduction are also described. Furthermore, novel isolated cDNA encoding the precursor of the novel gonadotropin-releasing hormone is disclosed. The use of such cDNA in controlling the gonadal development and spawning of fish is also described.
    Type: Grant
    Filed: December 5, 1994
    Date of Patent: July 1, 1997
    Assignees: University of Maryland Biotechnology Institute, University of Victoria Innovation and Development Corporation
    Inventors: Yonathan Zohar, Nancy M. Sherwood, Jean Rivier, Jim Powell, Yoav Gothilf
  • Patent number: 5593981
    Abstract: A method of treatment of androgen-related diseases such as prostate cancer in susceptible male animals, including humans, comprises administering novel antiandrogens and/or novel sex steroid biosynthesis inhibitors as part of a combination therapy. Sex steroid biosynthesis inhibitors, especially those capable of inhibiting conversion of dehydroepiandrosterone (DHEA) or 4-androstenedione (.DELTA..sup.4 -dione) to natural sex steroida (and testosterone into dihydrotestosterone) in peripheral tissues, are used in combination with antiandrogens usually after blockade of testicular hormonal secretions. Antiestrogens can also be part of the combination therapy. Pharmaceutical compositions and two, three, four and five component kits are useful for such combination treatment.
    Type: Grant
    Filed: September 10, 1993
    Date of Patent: January 14, 1997
    Assignee: Endorecherche Inc.
    Inventor: Fernand Labrie
  • Patent number: 5519002
    Abstract: A method for preventing conception in mammals wherein a composition containing (1) free LHRH or its analog and (2) an immunogenic conjugate between LHRH or its analog and a carrier protein is administered to the mammals Free LHRH or its analog acts to prevent conception in the mammal during the period from administration to about 6 weeks; the immunogenic conjugate acts to prevent conception during the period from about 6 weeks after administration until the LHRH antibodies formed in response to the conjugate are metabolized, generally about 0.5-2 years.
    Type: Grant
    Filed: March 1, 1993
    Date of Patent: May 21, 1996
    Assignee: Mallinckrodt Veterinary, Inc.
    Inventor: Abdus S. Mia
  • Patent number: 5476663
    Abstract: A microcapsule produced by preparing a water-in-oil emulsion comprising an inner aqueous layer containing said water-soluble drug and a drug retaining substance therefor and an oil layer containing a polymer substance, then thickening or solidifying said inner aqueous layer to a viscosity of not lower than about 5000 centiposes and finally subjecting the resulting emulsion to in water drying gives prolonged release of water-soluble drug.
    Type: Grant
    Filed: April 15, 1994
    Date of Patent: December 19, 1995
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Hiroaki Okada, Yasuaki Ogawa, Takatsuka Yashiki
  • Patent number: 5439688
    Abstract: A pharmaceutical composition is prepared in the form of microparticles or of an implant comprising a biodegradable polymer selected from poly-1,4-butylene succinate, poly-2,3-butylene succinate, poly-1,4-butylene fumarate and poly-2,3-butylene succinate, incorporating as the active substance the pamoate, tannate, stearate or palmitate of a natural or of a synthetic peptide comprising 3 to 45 amino acids, such as LH-RH, somatostatin, GH-RH or calcitonin, or one of their synthetic analogues or homologues. The preparation comprises dry blending the ingredients in the form of powders, pre-compressing and preheating the mixture and then extruding the pre-compressed and pre-heated mixture. The product resulting from the extrusion step can then be comminuted and finally sieved.
    Type: Grant
    Filed: November 12, 1991
    Date of Patent: August 8, 1995
    Assignee: Debio Recherche Pharmaceutique S.A.
    Inventors: Piero Orsolini, Frederic Heimgartner
  • Patent number: 5389613
    Abstract: A novel method of treating prostate adenocarcinoma, prostate benign hypertrophia, endometriosis, dysmenorrhea, hirsuitism, hormono-dependant mammary tumors, treatment and prevention of precocious puberty, induction of a retardation of the appearance of puberty and treatment of acne of mammals comprising administering to warm-blooded animals an effective amount of a peptide of the formulaP Glu-His-Trp-Ser-Tyr-X-Y-Arg-Pro-Z (I)wherein (a) Z is Gly--NH.sub.2, Y is Leu and X is Gly, (b) Z is Gly--NH.sub.2, Y is Leu, X is DN Leu, DN Val, D Abu (.alpha.-aminobutyric acid), D Phe, D Ser, D Thr, D Met, D Pgl, D Lys, Leu, Ile, Nle, Val, N Val, Met, Phe, D Leu, D Arg, D Ser (tbu), D Thr (tbu), D Cys (tbu), D Asp (O tbu), D Glu (Otbu), D Orn (boc), D Lys (boc), D Trp, Trp, 2-methyl Ala, D Tyr, D Met .epsilon.-lauryl D Lys, .epsilon.
    Type: Grant
    Filed: February 18, 1993
    Date of Patent: February 14, 1995
    Assignees: Roussel Uclaf, Shering Corporation
    Inventors: Fernand Labrie, Jean-Pierre Raynaud
  • Patent number: RE40119
    Abstract: A growth such as a tumor, hypertrophied tissue or cyst is biopsied or more completely excised subsequent to the administration of an effective amount of a gonadotropin releasing hormone analog or other inhibitor of ovarian steroid production or action.
    Type: Grant
    Filed: December 20, 2004
    Date of Patent: February 26, 2008
    Assignee: Eastern Virginia Medical School
    Inventor: Gary D. Hodgen